Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SPSB4 (SPRY domain-containing SOCS box protein 4) is an adaptor protein that forms part of a Cullin5-based E3 ubiquitin ligase complex, characterized by a central SPRY domain for substrate recognition and a C-terminal SOCS box domain for ubiquitin ligase assembly[1][2][7][8]. SPSB4 targets proteins, including NOS2, NR1D1, and EphB2, for ubiquitination and subsequent proteasomal degradation, thereby regulating nitric oxide production in macrophages, circadian transcriptional repressors, and EphB2-dependent cell signaling[4][7][8][9]. Dysregulation or mutation of SPSB4 is implicated in pathways relevant to inflammation, cancer (e.g., affecting apoptosis regulators like Par-4), and other diseases[1][7][9]. SPSB4 is a validated molecular target for modulating ubiquitin-proteasome degradation in selected cellular processes.
Ubiquitination and proteasomal degradation of substrate proteins, such as NOS2 (inducible nitric oxide synthase), NR1D1 (nuclear receptor involved in circadian rhythm), and EphB2 (receptor tyrosine kinase)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SPRY domain-containing SOCS box protein 4 (SPSB4).